Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Singh, N. [1 ]
Said, I. [1 ]
Faruqi, A. [1 ]
Gilks, B. [1 ]
Le, N. [1 ]
Boehm, S. [1 ]
机构：
[1] Barts Hlth NHS Trust, Dept Cellular Pathol, London, England
来源：
VIRCHOWS ARCHIV | 2014年 / 465卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-14-004
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer
    Koti, Madhuri
    Edwards, Andrew
    Squire, Jeremy A.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer
    Suzuki, Kazuhiro
    Yokoi, Akira
    Matsuzaki, Juntaro
    Yoshida, Kosuke
    Yamamoto, Yusuke
    Kato, Tomoyasu
    Ishikawa, Mitsuya
    Ochiya, Takahiro
    Kajiyama, Hiroaki
    CANCER MEDICINE, 2024, 13 (22):
  • [23] Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence for high-grade serous ovarian cancer patients with advanced disease
    Li, J.
    Wu, M-F.
    Li, H.
    Lin, Z-Q.
    Wang, L-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1336 - S1336
  • [24] Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
    Deen, Surrin S.
    Priest, Andrew N.
    McLean, Mary A.
    Gill, Andrew B.
    Brodie, Cara
    Crawford, Robin
    Latimer, John
    Baldwin, Peter
    Earl, Helena M.
    Parkinson, Christine
    Smith, Sarah
    Hodgkin, Charlotte
    Patterson, Ilse
    Addley, Helen
    Freeman, Susan
    Moyle, Penny
    Jimenez-Linan, Mercedes
    Graves, Martin J.
    Sala, Evis
    Brenton, James D.
    Gallagher, Ferdia A.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
    Surrin S. Deen
    Andrew N. Priest
    Mary A. McLean
    Andrew B. Gill
    Cara Brodie
    Robin Crawford
    John Latimer
    Peter Baldwin
    Helena M. Earl
    Christine Parkinson
    Sarah Smith
    Charlotte Hodgkin
    Ilse Patterson
    Helen Addley
    Susan Freeman
    Penny Moyle
    Mercedes Jimenez-Linan
    Martin J. Graves
    Evis Sala
    James D. Brenton
    Ferdia A. Gallagher
    Scientific Reports, 9
  • [26] BRCA1 expression, its correlation with clinicopathological features, and response to neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Patil, Akkamahadevi
    Patil, Sharada
    Anupama, C. E.
    Rajarajan, Savitha
    Nimbalkar, Vidya P.
    Amirtham, Usha
    Champaka, G.
    Suma, M. N.
    Patil, Geetha V.
    Nargund, Ashwini
    Pallavi, V. R.
    Jacob, Linu
    Premalatha, C. S.
    Prabhu, Jyothi S.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2023, 49 (12) : 2875 - 2882
  • [27] Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
    Lee, Yong Jae
    Woo, Ha Young
    Kim, Yoo-Na
    Park, Junsik
    Nam, Eun Ji
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    Park, Eunhyang
    Joung, Je-Gun
    Lee, Jung-Yun
    CANCERS, 2022, 14 (09)
  • [28] Molecular analysis of exceptional response in high-grade serous ovarian cancer.
    Garsed, Dale
    Pandey, Ahwan
    Fereday, Sian
    Alsop, Kathryn
    Wouters, Maartje
    Saner, Flurina
    Kennedy, Catherine
    Pearce, Celeste
    Pike, Malcolm
    Ramus, Susan
    Kobel, Martin
    deFazio, Anna
    Goode, Ellen
    Nelson, Brad
    Bowtell, David
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 18
  • [29] TISSUE IS THE ISSUE: CHEMOTHERAPY RESPONSE SCORE (CRS) IS MOST PREDICTIVE OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN ADVANCED, HIGH GRADE SEROUS OVARIAN CANCER
    Knickerbocker, A.
    Kuchta, K.
    Donaldson, C.
    Diaz Moore, E.
    Lippitt, M.
    Rodriguez, G.
    Watkin, W.
    Jenkins Vogel, T.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (01) : 165 - 165
  • [30] Targeting macrophages and regulatory T cells improves response to chemotherapy in high-grade serous ovarian cancer
    Elorbany, Samar
    Berlato, Chiara
    Carnevalli, Larissa
    Barry, Simon
    Maniati, Eleni
    Wang, Jun
    Manchanda, Ranjit
    Kzhyshkowska, Julia
    Balkwill, Frances
    CANCER RESEARCH, 2024, 84 (06)
12345